Replies to post #3081 on Rexahn Pharmaceuticals, Inc. (REXN)

[Theo]

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress

"ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced it will present the preliminary Phase Ib/IIa efficacy data for RX-3117 in metastatic pancreatic cancer and an update on the Supinoxin™ Phase I clinical trial at the 2016 European Society for Medical Oncology (ESMO) Congress, which will take place October 7th – 11th in Copenhagen, Denmark..."